As Executive Director and Head of Bioscience, Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF), 呼吸 & 免疫学(右&I), I lead more than 50 scientists across three sites in the UK, 美国和瑞典, supporting a portfolio of drug discovery and development projects from target identification through to completion of phase 2B studies. I am also a member of the Leadership Team and Research Board governing 澳门在线赌城娱乐’s 呼吸 & 免疫学(右&一)事业部.

With over 25 years’ experience in biopharmaceutical research and development, I have held positions including Senior Principle Scientist, 项目负责人, Head of Drug 新陈代谢 and Pharmacokinetics and Head of Bioscience. With over 45 peer reviewed publications, I am passionate about scientific discovery and supporting the scientists with whom I work through providing clarity, simplicity and time for science.

COPD和IPF, the teams I lead are focused on developing a pre-clinical portfolio targeting disease modification and cure. The long-term goal is to make discoveries that allow reversal of lung diseases, allowing patients to live healthy lives for longer.

I am a biochemistry graduate and also have a PhD in protein biochemistry and enzyme kinetics from the University of Birmingham, UK.


I am passionate about problem solving and addressing the granular details of scientific research so that we make truly informed clinical investment decisions. I feel privileged to work for an organisation that has scientific excellence as a core value underpinning investment decisions. 澳门在线赌城娱乐 really does have the desire to make a transformative difference to patients’ lives.

肯污垢 Executive Director and Head of Bioscience COPD & IPF、呼吸 & 免疫学(右&我),澳门在线赌城娱乐

肯污垢, Executive Director and Head of Bioscience COPD & IPF、呼吸 & 免疫学(右&我),澳门在线赌城娱乐

电流的作用

Executive Director and Head of Bioscience COPD & IPF、呼吸 & 免疫学(右&我),澳门在线赌城娱乐

2018年至今

Head of Bioscience, 呼吸 & 免疫学(右&我),澳门在线赌城娱乐, leading the biology support of preclinical and early clinical portfolio. Responsible for over 50 scientists across Sweden, US and UK.

2014 – 2019

高级主管, Head of Drug 新陈代谢 and Pharmacokinetics (DMPK), 呼吸, Inflammation and Autoimmunity, 澳门在线赌城娱乐, 哥德堡. Led a department of 25 - 30 scientists and delivered projects from early drug discovery through to Phase 2b investment decision and regulatory submissions.

2018 – 2020

项目负责人, 呼吸, Inflammation and Autoimmunity, 澳门在线赌城娱乐, 哥德堡. Led a Lead Optimization project building on previous experience as a deputy project leader (inhaled anti-muscarinic project for COPD), overseeing the successful nomination of three candidate drugs for clinical development.

2013 – 2014

Senior Principle Scientist and Head of In Vitro & 体内吸收, 分布, 新陈代谢, 和排泄(ADME), 呼吸, Inflammation and Autoimmunity, 澳门在线赌城娱乐, 哥德堡. Managed teams responsible for pre-clinical and clinical biotransformation, bioanalysis and in vitro and in vivo data production, interpretation and reporting phases.

2007 – 2011

Deputy project leader (inhaled anti-muscarinic project for COPD), overseeing the successful nomination of three candidate drugs for clinical development and the oral FPR1 antagonist project (COPD), co-leading the project through pre-clinical milestones.

Veeva ID: Z4-51941
Date of preparation: January 2023